Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsClover Health Actinic Keratosis Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentClover HealthPolicy N/A

    Actinic Keratosis Step Therapy Criteria

    Customize your policy alerts

    Sign up for all clover_health policy alerts

    Know when clover_health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Establishes step-therapy requirements for selected prescription products, including diclofenac sodium gel 3% and medications in antidepressant, atypical antipsychotic, SGLT2 inhibitor, and other therapy categories.

    Policy Summary
    PayerClover Health
    PolicyActinic Keratosis Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Last ReviewJan 1, 202745d
    Next Review DateN/A
    Key ActionDocument the required prerequisite medication trial or trials and, where applicable, that the request is for continuation of prior therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Diclofenac sodium gel 3%
    2Topical alternatives
    11Generic antidepressant alternatives
    7Generic antipsychotic alternatives
    AllowedPrior therapy exception

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Actinic keratosis initial therapy

    Covered after meeting the step-therapy requirement.

    Required topical trial: Trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3%1 of 2 alternatives

    Either alternative satisfies the criterion

    Antidepressant initial therapy

    Covered after meeting the step-therapy requirement.

    Generic antidepressant trials

    • Eligible alternatives: bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochloride

    Atypical antipsychotic initial therapy

    Covered after meeting the step-therapy requirement.

    Generic atypical antipsychotic trials

    • Eligible alternatives: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone

    Invega Hafyera initial therapy

    Covered for new starts after meeting the step requirement.

    Prior Invega therapy: Trial of Invega Sustenna or Invega Trinza1 agent

    Step applies to new starts only; continuation of prior therapy may be approved

    Lybalvi initial therapy

    Covered after meeting the step-therapy requirement.

    Generic olanzapine trial: Trial of one oral generic formulary olanzapine1 agent

    Continuation of prior therapy may be approved

    Farxiga initial therapy

    Covered after meeting the step-therapy requirement.

    Generic dapagliflozin trial: Trial of generic dapagliflozin1 agent

    New start requirement

    Initial therapy requires the following step.

    Required step: Trial of generic zonisamide capsule

    Applies to new starts only

    Continuation of prior therapy

    Continuation of prior therapy may be approved.

    Continuation approval: Approve for continuation of prior therapy

    Step requirement does not apply to continuation of prior therapy

    Documentation and Provider Actions

    Step Therapy

    Topical Fluorouracil or Imiquimod Trial

    Before diclofenac sodium gel 3% is authorized, document a trial of either topical fluorouracil or topical imiquimod for actinic keratosis.

    • Required prerequisite: trial of topical fluorouracil or topical imiquimod.
    • Document the agent tried and relevant trial history.
    Step Therapy

    Two Generic Antidepressant Trials

    For the antidepressant step, document trials of two generic formulary antidepressants before approval. Continuation of prior therapy may be approved when the member is already receiving the therapy.

    • Eligible generics: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine hydrochloride.
    • Document trials of two listed generic products, including drug names and trial history.
    • The step applies to new therapy; approve for continuation of prior therapy.

    Initial Therapy Criteria

    Diclofenac sodium gel 3%

    Initial therapy criterion.

    Topical alternative trial: Trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3%1 of 2 alternatives

    Affected antidepressants

    Initial therapy criterion.

    Generic antidepressant trials: Trial of two generics from the listed formulary antidepressants2 agents

    Continuation of prior therapy may be approved

    Affected atypical antipsychotics

    Continuation of Prior Therapy

    Antidepressant continuation

    Continuation of prior therapy may be approved.

    Continuation: Request is for continuation of prior antidepressant therapy

    Atypical antipsychotic continuation

    Continuation of prior therapy may be approved.

    Continuation: Request is for continuation of prior atypical antipsychotic therapy

    Invega Hafyera continuation

    Continuation of prior therapy may be approved.

    Continuation:

    Required Step Therapy

    ProductRequired prior therapy
    Diclofenac sodium gel 3%Trial of either topical fluorouracil or topical imiquimod
    Affected productsRequired prior therapy
    Affected antidepressantsTrial of two generics among bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine hydrochloride. Continuation of prior therapy may be approved.
    Affected productsRequired prior therapy
    Affected atypical antipsychoticsTrial of two oral generic formulary agents among asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. Continuation of prior therapy may be approved.
    ProductRequired prior therapyApplicability
    Invega HafyeraTrial of Invega Sustenna or Invega TrinzaNew starts only; continuation of prior therapy may be approved
    ProductRequired prior therapy
    LybalviTrial of one oral generic formulary olanzapine. Continuation of prior therapy may be approved.
    ProductRequired prior therapy
    FarxigaTrial of generic dapagliflozin
    ProductRequired prior therapyApplicability
    Zonisade suspensionTrial of generic zonisamide capsulesNew starts only; the step requirement does not apply to continuation of prior therapy
    Policy Summary
    PayerClover Health
    PolicyActinic Keratosis Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Last ReviewJan 1, 202745d
    Next Review DateN/A
    Key ActionDocument the required prerequisite medication trial or trials and, where applicable, that the request is for continuation of prior therapy.
    SourceLink
    On This Page
    Coverage CriteriaDocumentation and Provider ActionsInitial Therapy CriteriaContinuation of Prior TherapyRequired Step Therapy
    Step Therapy

    Two Generic Atypical Antipsychotic Trials

    Before approval of the affected atypical antipsychotic therapy, document trials of two oral generic formulary atypical antipsychotic agents. Continuation of prior therapy may be approved.

    • Eligible agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    • Document trials of two listed oral generic agents, including drug names and trial history.
    • Approve for continuation of prior therapy.
    Step Therapy

    Invega Hafyera New-Start Step

    For new starts of Invega Hafyera, document a trial of Invega Sustenna or Invega Trinza before approval. This step applies only to new starts; continuation of prior therapy may be approved.

    • Required prerequisite: trial of Invega Sustenna or Invega Trinza.
    • Clearly distinguish a new start from continuation of prior therapy.
    • Approve for continuation of prior therapy.
    Step Therapy

    Generic Olanzapine Trial

    Before approval of Lybalvi, document a trial of one oral generic formulary olanzapine. Continuation of prior therapy may be approved.

    • Required prerequisite: trial of one oral generic formulary olanzapine.
    • Document the product and trial history.
    • Approve for continuation of prior therapy.
    Step Therapy

    Generic Dapagliflozin Trial

    Before approval of Farxiga, document a trial of generic dapagliflozin.

    • Required prerequisite: trial of generic dapagliflozin.
    • Document the product and trial history.
    Step Therapy

    Generic Zonisamide Trial for New Starts

    For new starts of Zonisade suspension, document a trial of generic zonisamide capsules first. The step applies only to new starts; continuation of prior therapy may be approved.

    • Required prerequisite for new starts: trial of generic zonisamide capsule.
    • Clearly distinguish a new start from continuation of prior therapy.
    • Approve for continuation of prior therapy.

    Initial therapy criterion.

    Generic atypical antipsychotic trials: Trial of two listed oral generic formulary atypical antipsychotic agents2 agents

    Continuation of prior therapy may be approved

    Invega Hafyera

    Initial therapy criterion.

    Prior Invega therapy: Trial of Invega Sustenna or Invega Trinza1 agent

    Step applies to new starts only; continuation of prior therapy may be approved

    Lybalvi

    Initial therapy criterion.

    Generic olanzapine trial: Trial of one oral generic formulary olanzapine1 agent

    Continuation of prior therapy may be approved

    Farxiga

    Initial therapy criterion.

    Generic dapagliflozin trial: Trial of generic dapagliflozin1 agent

    Trial of generic zonisamide capsule

    Initial therapy criterion.

    Required step: Trial of generic zonisamide capsule

    Step applies to new starts only

    Request is for continuation of prior Invega Hafyera therapy

    The step applies to new starts only

    Lybalvi continuation

    Continuation of prior therapy may be approved.

    Continuation: Request is for continuation of prior Lybalvi therapy

    Continuation of prior therapy

    Continuation of prior therapy may be approved.

    Continuation approval: Approve for continuation of prior therapy

    Step applies to new starts only